Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: Association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis

Molecular Carcinogenesis

Volumn 51, Issue 10, 2012, Pages 816-825

  Stärkel, Peter ^a   Charette, Nicolas ^a   Borbath, Ivan ^a   Schneider Merck, Tanja ^a   De Saeger, Christine ^a   Abarca, Jorge ^a   Leclercq, Isabelle ^a   Horsmans, Yves ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Diethylnitrosamine; NFkB; Oncogenes; Pro inflammatory cytokines; Stat3

Indexed keywords

DIETHYLNITROSAMINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; PROTEIN P70; RAS PROTEIN; S6 KINASE; SALIRASIB; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LIVER CELL CARCINOMA; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL CYCLE; CELL PROLIFERATION; CYCLIN D; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FARNESOL; INFLAMMATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RATS; RATS, WISTAR; SALICYLATES; STAT3 TRANSCRIPTION FACTOR;

RATTUS;

EID: 84866182508     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20849     Document Type: Article

References (31)

1. Llovet MJ, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-S37.
2. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. Semin Liver Dis 2010; 30: 35-51.
3. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
4. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-1074.
5. Haklai R, Gana Weisz M, Elad G, et al. Dislodgment and accelerated degradation of ras. Biochemistry 1998; 37: 1306-1314.
6. Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. Supression of lung cancer tumor growth in a nude Mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 2007; 6: 1765-1773.
7. Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y. Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1999; 1452: 228-242.
8. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 1995; 270: 22263-22270.
9. Schneider-Merck T, Borbath I, Charette N, et al. The ras inhibitor Farnesylthiosalicylic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats. Eur J Cancer 2009; 45: 2050-2060.
10. Da Silva Morais A, Saliez A, Leclercq I, Horsmans Y, Stärkel P. Inhibition of the ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. Clin Sci 2008; 114: 73-83.
11. Charrette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer 2010; 9: 256-270.
12. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: End of the beginning. J Hepatol 2006; 44: 798-805.
13. Marciano D, Ben-Baruch G, Marom M, Egozi Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 1995; 38: 1267-1272.
14. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307-314.
15. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol 2008; 48: 858-879.
16. Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-1311.
17. Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist pioglitazonz inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 2007; 43: 1755-1763.
18. He G, Karin M. NF-κB and STAT3-Key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
19. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010; 1: a000109.
20. Frank DA. Stat3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251: 199-210.
21. Ram PT, Iyengar R. G protein coupled receptor signalling through the Src and Stat3 pathway: Role in proliferation and transformation. Oncogene 2001; 20: 1601-1606.
22. Yeh HH, Giri R, Chang TY, Chou CY, Su WC, Liu HS. Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell. DNA Cell Biol 2009; 28: 131-139.
23. Plaza-Menacho I, van der Sluis T, Hollema H, et al. Ras/ERK1/2-mediated Stat3 Ser727 phosphorylation by familial medullary throid carcinoma-associated RET mutants induces full activation of Stat3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J Biol Chem 2007; 282: 6415-6424.
24. Kim DJ, Chan KS, Sano S, DiGiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog 2007; 46: 725-731.
25. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103: 10544-10551.
26. He G, Karin M. NF-kB and STAT3-key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
27. Denhardt DT. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: Synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog 1996; 7: 261-291.
28. Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodelling. Biochem Cell Biol 2005; 83: 1-14.
29. Arthur JSC. MSK activation and physiological roles. Front Biosci 2008; 13: 5866-5879.
30. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: A new target in cancer therapy. Curr Cancer Drug Targets 2010; 10: 484-495.
31. Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010; 141: 178-190.